Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIn the UK, private Mounjaro prices typically range from roughly £149 to £375 per monthly pen, depending on the dose and the provider — and every legitimate price must include a prescription issued after a clinical assessment. That figure shifted significantly when Eli Lilly raised its UK list price from around £122 to around £330 per pen for the highest dose on 1 September 2025, pushing private market prices upward across the board. Mounjaro (tirzepatide) is a prescription-only medicine, so any quoted price reflects not just the physical pen but the clinical infrastructure behind it. The NICE appraisal of tirzepatide (TA1026) and the prescriber who reviews your case are what make the treatment safe and legal.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks is some version of: "I saw it for £X somewhere, why is yours different?" It is a fair question, and the honest answer is that the number on the page rarely tells the whole story.
Many providers quote only the cost of the pen itself, then add consultation fees, prescription charges and delivery on top. Some charge monthly subscription fees that continue even when you pause treatment. Others charge separately for dose-review appointments or aftercare calls. By the time you add those up, a low headline figure and a fully inclusive one can end up remarkably close, or the apparently cheaper route turns out more expensive.
Since Eli Lilly's September 2025 list-price change, the gap between dose levels has also widened considerably. A 2.5mg starter pen and a 15mg maintenance pen are priced very differently, so the month you start treatment and the month you reach your maintenance dose carry different costs. Any provider that quotes you one flat price for the whole treatment journey without asking what dose you are on deserves a closer look. You can read more about how Mounjaro costs are structured across the titration schedule.
The supply-chain story matters here too. Reported wholesale price increases feed directly into what private services charge, you can see how Mounjaro's wholesale pricing flows through to what patients pay.
A lawful private Mounjaro prescription requires a clinical assessment by a qualified prescriber, documentation of that assessment, an actual prescription, dispensing by a registered pharmacy and, usually, some form of ongoing clinical oversight. These are not optional extras, they are what makes the medicine legal to supply.
At nume, one transparent price covers the consultation, the prescription, the medicine and free next-working-day delivery. There are no bolt-on charges for aftercare and no subscription that renews without your say-so. Every repeat order gets a fresh clinical review before anything is dispatched. That review is done by a GPhC-registered Independent Prescriber, a named clinician reads your answers, not an automated system.
We are not the cheapest option in the market, and that is a deliberate choice. The question worth asking is not which service charges least, but which one includes the most, because cutting corners on the clinical side of a prescription medicine is where things go wrong. You can verify our pharmacy on the GPhC register (premises number 9012878).
If you want to understand how prices have shifted since the Lilly price change, this page on Mounjaro costs through 2025 sets out what happened and why.
Price is a reasonable thing to think about. It is just not the right filter to apply first to a prescription-only medicine.
The MHRA has seized roughly 20 million doses of illegally traded weight-loss medicines with a street value of around £45 million, and in October 2025 shut down the first known UK site manufacturing counterfeit tirzepatide pens. Some fake pens have contained insulin. The sellers behind them advertise aggressively online, often at prices well below the market rate, sometimes with discount codes as the hook. For a legitimately supplied prescription medicine, codes like that do not exist, and if a seller is offering them, that is a red flag worth taking seriously.
The MHRA's Yellow Card scheme lets you report suspected fake sellers. Any online pharmacy you use should be verifiable on the GPhC register; if it is not listed, do not order from it. Worth checking before you pay anything.
What the price of Mounjaro buys you, when it is supplied properly, is more than the pen. It is the prescriber's judgment about whether this is right for you, the dispensing pharmacist's check, the supply chain audit and the clinical backup if something goes wrong. How high Mounjaro doses go also affects overall treatment cost, and understanding the full picture matters before committing to a provider.
If you are curious about likely results alongside the cost question, you can read about how much you might lose on Mounjaro as a separate question worth working through too. Clinical trials, NICE's review and real-world prescribing all paint a consistent picture, but those results come from properly supervised treatment, not from a pen bought without a prescription.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.